Oxomemazine
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Oxomemazine is a phenothiazine derivative antihistamine indicated in the treatment of allergies.
- Generic Name
- Oxomemazine
- DrugBank Accession Number
- DB13820
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 330.45
Monoisotopic: 330.14019913 - Chemical Formula
- C18H22N2O2S
- Synonyms
- Oxomemazine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination for symptomatic treatment of Cold Combination Product in combination with: Guaifenesin (DB00874) ••• ••• ••••• Used in combination for symptomatic treatment of Coughing Combination Product in combination with: Guaifenesin (DB00874) ••• ••• ••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
Pathway Category Oxomemazine H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareDroxidopa The therapeutic efficacy of Droxidopa can be increased when used in combination with Oxomemazine. Ephedrine The therapeutic efficacy of Ephedrine can be increased when used in combination with Oxomemazine. Epinephrine The therapeutic efficacy of Epinephrine can be increased when used in combination with Oxomemazine. Levonordefrin The therapeutic efficacy of Levonordefrin can be increased when used in combination with Oxomemazine. Norepinephrine The therapeutic efficacy of Norepinephrine can be increased when used in combination with Oxomemazine. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- R06AD08 — Oxomemazine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzothiazines
- Sub Class
- Phenothiazines
- Direct Parent
- Phenothiazines
- Alternative Parents
- Alkyldiarylamines / Benzenoids / 1,4-thiazines / Sulfones / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alkyldiarylamine / Amine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 305MB38V1C
- CAS number
- 3689-50-7
- InChI Key
- QTQPVLDZQVPLGV-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H22N2O2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)23(21,22)18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3
- IUPAC Name
- 10-[3-(dimethylamino)-2-methylpropyl]-10H-5lambda6-phenothiazine-5,5-dione
- SMILES
- CC(CN(C)C)CN1C2=CC=CC=C2S(=O)(=O)C2=CC=CC=C12
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0240230
- ChemSpider
- 18281
- ChEBI
- 135408
- ChEMBL
- CHEMBL2104734
- Wikipedia
- Oxomemazine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Syrup Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0856 mg/mL ALOGPS logP 2.81 ALOGPS logP 3.18 Chemaxon logS -3.6 ALOGPS pKa (Strongest Basic) 8.02 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 40.62 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 94.22 m3·mol-1 Chemaxon Polarizability 35.83 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0k96-9772000000-3ec457a1ac6a72f2456b Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-0209000000-8230848c8ef487a57a15 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-0039000000-855e2c0b130dafa40436 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-05ai-9344000000-996e94a9bcf109bdf527 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-0039000000-4ffe12048840a05a1fe9 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-000x-0390000000-e7fd87cff10e9c35e20c Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0bu0-4090000000-234eaa5e5cc6176c4072 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 188.531346 predictedDarkChem Lite v0.1.0 [M-H]- 169.9164 predictedDeepCCS 1.0 (2019) [M+H]+ 189.254346 predictedDarkChem Lite v0.1.0 [M+H]+ 172.27438 predictedDeepCCS 1.0 (2019) [M+Na]+ 188.869146 predictedDarkChem Lite v0.1.0 [M+Na]+ 178.36754 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:49 / Updated at May 21, 2021 10:23